Clovis Oncology Inc (NASDAQ:CLVS) Q4 2016 Sentiment Report

BNC Bancorp (NASDAQ:BNCN) has risen 39.77% since May 23, 2016 and is uptrending. (NASDAQ:CLVS) stock have an ABR of 1.86.

Winslow Capital Management Llc decreased Amazon.Com Inc (AMZN) stake by 20.8% reported in 2016Q4 SEC filing. We have $34.32 PT which if reached, will make NASDAQ:BNCN worth $70.00 million more.

Consonance Capital Management Lp, which manages about $513.80 million and $910.58 million US Long portfolio, upped its stake in Atricure Inc (NASDAQ:ATRC) by 2.43M shares to 2.67M shares, valued at $52.18 million in 2016Q4, according to the filing. FMR LLC now owns 1,816,859 shares of the biopharmaceutical company's stock valued at $115,679,000 after buying an additional 1,327,703 shares during the last quarter.

Clovis Oncology, Inc. was upgraded to " by analysts at JP Morgan. The stock's average target of $42.82 is -22.43% below today's ($55.2) share price. About 91,234 shares traded. It has outperformed by 266.01% the S&P500.

Since January 1, 0001, it had 0 insider buys, and 1 insider sale for $200,970 activity. They expect $0.54 EPS, down 3.57% or $0.02 from last year's $0.56 per share. Foot Locker Inc (NYSE:FL) was reduced too.

05/16/2017 - Clovis Oncology, Inc. had its "buy" rating reiterated by analysts at Bank of America Merrill Lynch.

COPYRIGHT VIOLATION NOTICE: "Clovis Oncology (CLVS) Earns Daily News Impact Rating of -0.03" was first reported by Markets Daily and is the property of of Markets Daily.

While looking at the SMA values of Clovis Oncology, Inc. SunTrust has "Buy" rating and $50 target. The rating was maintained by Suntrust Robinson with "Buy" on Friday, September 23. Mizuho maintained the stock with "Neutral" rating in Wednesday, August 24 report. As per Monday, April 4, the company rating was reinitiated by Piper Jaffray. Two analysts have rated the stock with a sell rating, five have given a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. Finally, Morgan Stanley restated an "overweight" rating and set a $79.00 price target on shares of Clovis Oncology in a research report on Tuesday, May 2nd. The original version of this article can be accessed at https://www.thecerbatgem.com/2017/05/25/clovis-oncology-inc-clvs-posts-earnings-results-beats-estimates-by-0-10-eps-updated-updated.html.

Investors sentiment decreased to 1.03 in Q4 2016. Its down 0.97, from 2 in 2016Q3. 38 funds opened positions while 42 raised stakes.

04/18/2017 - Credit Suisse began new coverage on Clovis Oncology, Inc. giving the company a " rating. Bnp Paribas Arbitrage Sa holds 0% or 2,276 shares. Geode Mngmt Ltd Limited Liability Company reported 290,450 shares stake.

On April 8, 2016, the U.S. Food and Drug Administration revealed that Clovis Oncology Inc had concealed that rociletinib was not well tolerated, and that serious adverse events were reported in 47% of patients treated with the drug. Jasper Ridge Ptnrs LP accumulated 4,592 shares. Voloridge Inv Mgmt Limited Com holds 183,693 shares or 0.18% of its portfolio. Marshall Wace Limited Liability Partnership owns 83,014 shares for 0.02% of their portfolio. Blackrock Institutional Trust Na holds 0.01% or 912,651 shares. Geode Capital Management Limited Company reported 0.01% stake.

Want to see what other hedge funds are holding CLVS? Sei Investments has 7,400 shares. Therefore 50% are positive.

Several other equities analysts also recently commented on the stock. The firm has "Buy" rating given on Tuesday, January 26 by Gabelli.

03/15/2017 - Clovis Oncology, Inc. had its "neutral" rating reiterated by analysts at Goldman Sachs. The stock of BNC Bancorp (NASDAQ:BNCN) earned "Mkt Perform" rating by Keefe Bruyette & Woods on Tuesday, November 29. The rating was downgraded by WallachBeth Capital to "Hold" on Tuesday, November 17. Raymond James upgraded BNC Bancorp (NASDAQ:BNCN) on Monday, May 9 to "Outperform" rating. 2,306 shares were sold by Jassy Andrew R, worth $1.93 million. Shares for $845,362 were sold by McInnis Matthew W. 626 shares were sold by Reynolds Shelley, worth $524,339 on Wednesday, February 15. The firm's market capitalization is $2.48 billion. The Bank is a full service commercial bank, which provides a range of banking services tailored to the particular banking needs of the communities it serves.

Price to Earning P/E ratio and Forward P/E stand at 0 and 0 respectively.